DK1121111T3 - Forbindelser til behandling af vægttab - Google Patents
Forbindelser til behandling af vægttabInfo
- Publication number
- DK1121111T3 DK1121111T3 DK99947762.3T DK99947762T DK1121111T3 DK 1121111 T3 DK1121111 T3 DK 1121111T3 DK 99947762 T DK99947762 T DK 99947762T DK 1121111 T3 DK1121111 T3 DK 1121111T3
- Authority
- DK
- Denmark
- Prior art keywords
- patient
- receptor antagonist
- weight loss
- inhibitor
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9822459.5A GB9822459D0 (en) | 1998-10-15 | 1998-10-15 | Method of treatment |
GBGB9822458.7A GB9822458D0 (en) | 1998-10-15 | 1998-10-15 | Methods of treatment |
GBGB9917181.1A GB9917181D0 (en) | 1999-07-23 | 1999-07-23 | Methods of treatment |
PCT/GB1999/003302 WO2000021509A2 (en) | 1998-10-15 | 1999-10-15 | Methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1121111T3 true DK1121111T3 (da) | 2010-05-31 |
Family
ID=27269516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99947762.3T DK1121111T3 (da) | 1998-10-15 | 1999-10-15 | Forbindelser til behandling af vægttab |
Country Status (9)
Country | Link |
---|---|
US (2) | US7417038B1 (da) |
EP (1) | EP1121111B1 (da) |
JP (1) | JP2002527378A (da) |
AT (1) | ATE457169T1 (da) |
CY (1) | CY1110282T1 (da) |
DE (1) | DE69942009D1 (da) |
DK (1) | DK1121111T3 (da) |
PT (1) | PT1121111E (da) |
WO (1) | WO2000021509A2 (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7417038B1 (en) * | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
US20040122067A1 (en) * | 2002-12-20 | 2004-06-24 | Lin Zhao | Treatment of chronic heart failure |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
PL1689378T3 (pl) | 2003-12-02 | 2009-09-30 | Sanol Arznei Schwarz Gmbh | Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
EP2332526A3 (en) | 2005-10-21 | 2011-10-12 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
IE20050723A1 (en) * | 2005-10-28 | 2007-05-30 | Patrick T Prendergast | Anti-mineralocorticoid therapy of infection |
US8735356B2 (en) | 2006-06-15 | 2014-05-27 | Ucb Pharma Gmbh | Anticonvulsant combination therapy |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
EP2998314B1 (en) | 2007-06-04 | 2020-01-22 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINE DERIVATIVE |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009257174A1 (en) * | 2008-06-09 | 2009-12-17 | Dimerix Bioscience Pty Ltd | Novel receptor hetero-dimers/-oligomers |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
CA2732513C (en) | 2008-08-01 | 2017-04-25 | Arca Biopharma, Inc. | Methods and compositions involving (s)-bucindolol |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
GB0907350D0 (en) | 2009-04-29 | 2009-06-10 | Myotec Therapeutics Ltd | Methods |
CA2786443C (en) | 2010-01-14 | 2018-12-11 | Novartis Ag | Use of an adrenal hormone-modifying agent |
KR20120125357A (ko) | 2010-02-10 | 2012-11-14 | 노파르티스 아게 | 근육 성장을 위한 방법 및 화합물 |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
KR20130074808A (ko) * | 2011-12-16 | 2013-07-05 | 한올바이오파마주식회사 | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
PL2968226T3 (pl) | 2013-03-14 | 2019-03-29 | Actimed Therapeutics Ltd | Kompozycje oksprenololu do leczenia raka |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
EP2832357A1 (en) | 2013-07-29 | 2015-02-04 | Charité - Universitätsmedizin Berlin | Selective AT2 receptor agonists for use in treatment of cachexia |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
WO2017144977A1 (en) | 2016-02-26 | 2017-08-31 | Act Ventures Ltd. | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness |
RU2019114228A (ru) | 2016-10-14 | 2020-11-16 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
US10772869B1 (en) | 2019-07-24 | 2020-09-15 | ECI Pharmaceuticals, LLC | Pharmaceutical compositions including carvedilol and methods of using the same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541188A (en) * | 1987-09-15 | 1996-07-30 | The Rowett Research Institute | Therapeutic applications of beta-adrenergic agonists |
CA1337432C (en) | 1988-03-23 | 1995-10-24 | Raymond M. Xhonneux | Method of lowering the blood pressure |
US6545040B1 (en) * | 1988-03-23 | 2003-04-08 | Janssen Pharmaceutica N.V. | Method of lowering the blood pressure |
CA2069404A1 (en) * | 1989-11-21 | 1991-05-22 | Timothy J. Barberich | Use of optically pure s(-) atenolol for the treatment of cardiovascular disorders |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
AU5354196A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist |
JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
AUPO274596A0 (en) | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
GB9714675D0 (en) | 1997-07-11 | 1997-09-17 | Smithkline Beecham Plc | Novel composition |
US7417038B1 (en) * | 1998-10-15 | 2008-08-26 | Imperial Innovations Limited | Methods of treating cachexia |
GEP20043302B (en) * | 2000-01-31 | 2004-02-10 | Pfizer Prod Inc | Nicotinamide Benzofused-Heterocyclyl Derivatives Useful as Selective Inhibitors of PDE4 Isozymes |
ATE409475T1 (de) * | 2001-02-20 | 2008-10-15 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
EP1793818A2 (en) | 2004-09-17 | 2007-06-13 | Neurocure Ltd. | Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
US20060069086A1 (en) | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
EP1990049A3 (en) | 2005-03-21 | 2008-11-26 | Vicus Therapeutics SPE 1, LLC | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) |
US8080528B2 (en) * | 2005-12-22 | 2011-12-20 | The Releef Initiative | Compositions and methods for treatment of cachexia |
AU2007221135A1 (en) | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
BRPI0718596B8 (pt) | 2006-11-09 | 2021-05-25 | Boehringer Ingelheim Int | composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina |
DK2155180T3 (da) | 2007-04-24 | 2016-09-12 | Acacia Pharma Ltd | Lægemiddelkombination og dets anvendelse til behandling af muskeltab |
CA2753844A1 (en) | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
-
1999
- 1999-10-15 US US09/807,558 patent/US7417038B1/en not_active Expired - Fee Related
- 1999-10-15 JP JP2000575485A patent/JP2002527378A/ja active Pending
- 1999-10-15 PT PT99947762T patent/PT1121111E/pt unknown
- 1999-10-15 DE DE69942009T patent/DE69942009D1/de not_active Expired - Lifetime
- 1999-10-15 AT AT99947762T patent/ATE457169T1/de active
- 1999-10-15 WO PCT/GB1999/003302 patent/WO2000021509A2/en active Application Filing
- 1999-10-15 EP EP99947762A patent/EP1121111B1/en not_active Expired - Lifetime
- 1999-10-15 DK DK99947762.3T patent/DK1121111T3/da active
-
2008
- 2008-08-15 US US12/192,780 patent/US7829596B2/en not_active Expired - Fee Related
-
2010
- 2010-05-10 CY CY20101100408T patent/CY1110282T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7829596B2 (en) | 2010-11-09 |
EP1121111A2 (en) | 2001-08-08 |
US20090023639A1 (en) | 2009-01-22 |
CY1110282T1 (el) | 2015-01-14 |
WO2000021509A3 (en) | 2000-11-09 |
JP2002527378A (ja) | 2002-08-27 |
ATE457169T1 (de) | 2010-02-15 |
DE69942009D1 (de) | 2010-03-25 |
PT1121111E (pt) | 2010-05-17 |
WO2000021509A2 (en) | 2000-04-20 |
EP1121111B1 (en) | 2010-02-10 |
US7417038B1 (en) | 2008-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1121111T3 (da) | Forbindelser til behandling af vægttab | |
ATE334985T1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
IL149890A0 (en) | Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated | |
NO990912D0 (no) | Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse | |
UA49869C2 (uk) | Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора | |
WO2004017941A3 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
MY114347A (en) | Synergistic therapeutic compositions and methods. | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
CA2378613A1 (en) | Selective iglur5 receptor antagonists for the treatment of migraine | |
ATE401913T1 (de) | Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation | |
WO2006053014A3 (en) | Selective inhibition of rock1 in cardiac therapy | |
EP1090635A3 (en) | Use of ferulic acid for treating hypertension | |
DE69733557D1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
WO2000048446A3 (en) | Use of antagonists of pg-e for the treatment of neuropathic pain | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
WO2001055176A3 (en) | Methods for inhibiting smooth muscle cell proliferation | |
MX2011013541A (es) | Agente terapeutico para la hipertension o de la presion sanguinea normal elevada. | |
WO2000076457A3 (en) | Il-8 receptor antagonists | |
ES2194378T3 (es) | Uso de antagonistas del receptor 5ht1a para prevenir y/o tratar la epilepsia lobular temporal. | |
WO2005094797A3 (en) | Use of ampa-receptor antagonists for treating dementia | |
DE69923982D1 (de) | Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten | |
WO2004011018A3 (en) | Methods of identifying selective beta-1-adrenergic receptor antagonists | |
ECSP003564A (es) | ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA |